Mechanism of Action
Nicotinic Receptor Antagonism
Catestatin acts as a non-competitive antagonist at nicotinic acetylcholine receptors (nAChRs) on adrenal chromaffin cells. By blocking nicotinic signaling, it reduces acetylcholine-stimulated catecholamine secretion, effectively dampening sympathoadrenal output. This mechanism is distinct from beta-blockers and provides a physiological feedback loop where CgA-derived catestatin limits its own precursor's (catecholamine) release.
Cardiovascular and Vasodilatory Effects
Catestatin produces vasodilation via endothelial nitric oxide synthase (eNOS) activation, increasing NO production and reducing vascular resistance. In isolated heart preparations, catestatin exerts negative inotropy and chronotropy independent of adrenergic pathways. It also activates the PI3K/Akt pathway in cardiomyocytes, conferring protection against ischemia-reperfusion injury. These combined effects reduce both preload and afterload.
Immune Modulation
Catestatin acts on macrophages and mast cells to modulate inflammatory responses. It inhibits LPS-induced TNF-alpha and IL-6 production while promoting anti-inflammatory M2 macrophage polarization. It also inhibits mast cell degranulation triggered by various stimuli, reducing histamine and inflammatory mediator release. This positions catestatin as a link between the autonomic nervous system and innate immunity.
Research Summary
Hypertension
PreclinicalAnimal studies consistently show blood pressure reduction with catestatin administration. Human genetic studies have found that CgA variants with reduced catestatin production correlate with higher blood pressure and hypertension prevalence. Plasma catestatin levels are lower in hypertensive patients compared to normotensive controls, supporting a physiological antihypertensive role.
Cardioprotection
PreclinicalIn rodent models of myocardial infarction and ischemia-reperfusion, catestatin reduces infarct size, preserves ejection fraction, and decreases cardiomyocyte apoptosis. Mechanisms involve Akt/ERK activation and mitochondrial permeability transition pore inhibition. These findings suggest potential utility in acute cardiac events, though clinical translation remains unexplored.
Metabolic Effects
Early ResearchCatestatin improves insulin sensitivity in high-fat diet rodent models, partly through adipose tissue modulation and reduced inflammatory signaling. It also influences adipokine secretion, reducing leptin/" class="wiki-internal-link">leptin and increasing adiponectin. These metabolic effects may be secondary to sympathoadrenal suppression, as catecholamine excess drives insulin resistance.
Calculate your Catestatin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Cardiovascular research | 0.3-1 nmol/kg IV | Acute (single dose) | IV infusion |
| Cardioprotection model | 1-3 nmol/kg IV | Pre-ischemia | IV bolus |
| Metabolic study | 100-300 pmol/kg/min | Continuous infusion | IV |
No established human dosing protocols. All parameters from animal research only.
Interactions
Safety Profile
Catestatin is an endogenous peptide with low inherent toxicity at physiological concentrations. Animal studies using supraphysiological doses show hypotension as the primary adverse effect. No human clinical trials have been conducted for exogenous catestatin administration. Short half-life limits sustained effects. Caution warranted in individuals on antihypertensives or with autonomic dysfunction.
References
- [1]Mahata SK, et al. Novel autocrine feedback control of catecholamine release. Nature. 1997;382:77-80.
- [2]Bassino E, et al. Catestatin mediates the cardiovascular effects of chromogranin A. Hypertension. 2015.
- [3]Muntjewerff EM, et al. Catestatin as a target in inflammatory and metabolic disease. Front Endocrinol. 2018.